Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Binding Assays

Binding assays are a vital tool used to characterize the interaction of compounds with their target, providing information rich data to help guide your discovery program. The bioscientists at Sygnature Discovery have extensive experience in developing a wide range of binding assay in a variety of formats, ensuring your project has the tailored assay solution it requires.

Radioligand binding

Radioligand binding assays are widely used to characterise the binding of drugs to their targets (enzyme, receptor etc.) especially when the native ligand is difficult to label by other means (e.g. fluorescence). Sygnature Discovery has a radiochemical usage license, allowing the development of biological assays using the state-of-the-art Hidex Sense Beta to quantify radioligand-bound target.

Using a competition binding format, we can determine the affinity at equilibrium of unlabeled compounds. Radioligand binding assays also enable us to explore the binding mechanism of drug-like molecules, and by conducting a time-course it is possible to determine binding kinetics.

  • Cell membranes prepared in-house
  • Permit to use 3H, 14C, 32P, 33P, 35S and 125I
  • Determine affinity constant (Ki) for drug-target interaction
  • Association (kon) and dissociation (koff) rate constants may be estimated
  • Distinguish competitive from non-competitive binders




Fluorescence Polarization (FP)

Fluorescence polarization (FP) is a robust and sensitive technique used to measure the binding between two molecules in solution: a fluorescently labelled tracer and a larger unlabeled binding partner. In FP, the molecular rotation of the tracer leads to depolarization of plane polarized incident light, emitted as a fluorescent signal. Interaction of the tracer with its binding partner slows the molecular tumbling of the tracer and reduces the degree of depolarization, allowing a measurement of the interaction and the effect of small molecule inhibitors on this.

  • FP can be measured in microplates rapidly and with a high degree of precision, making it a technique highly suitable for compound screening and derivation of IC50
  • At Sygnature Discovery FP assays are, if possible, miniaturized (5 µL sample volume), leading to low reagents consumption and high throughput.
  • FP is performed with all components in solutions, making it a complementary technique to Surface Plasmon Resonance (SPR), another biophysical technique used extensively at Sygnature Discovery.

Sygnature Discovery utilizes the PHERAstar® FSX platform as a plate reader for FP detection, providing unparalleled sensitivity, speed and ease of use.


Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.